Saturday 17 October 2026
Export CLNN’s income statement to Excel — free account
Clene Inc.
CLNN Healthcare Biotechnology
Clene Inc.’s revenue for fiscal 2025 (year ended December 2025) was $200,000.00, down 41.5% from fiscal 2024. In the quarter to June 2026, revenue grew 233.3%, EPS fell 38.5%, free cash flow grew 45.4% and total debt rose 16.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
3.10
0.21
−6.34%
Follow CLNN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Jan '22 | Dec '21 | Jan '21 | Dec '20 | Jan '20 | Dec '19 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 3 | 3 | 1 | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
(27.14) | (17.56) | (8.24) | (8.30) | — | (2.30) | — | (1.55) | — | — |
P/S ratio |
289.36 | 107.97 | 46.53 | 130.96 | 376.33 | 349.08 | 643.23 | 919.38 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(65.16) | (40.63) | (18.27) | (19.12) | — | (8.45) | — | (4.39) | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
— | (6.10) | (4.26) | 2.66 | — | 2.04 | — | — | — | — |
P/Operating CF |
(12.06) | (7.59) | (4.24) | (8.03) | (28.32) | (26.27) | (22.81) | (32.61) | (14.29) | — |
P/B ratio |
0.00 | 0.00 | 2.27 | 19.14 | 21.60 | 20.04 | 388.58 | 555.41 | 0.00 | — |
Price to Tangible BV |
0.00 | 0.00 | 2.27 | 19.14 | 21.60 | 20.04 | 388.58 | 555.41 | 0.00 | — |
EV/Sales |
331.12 | 117.53 | 11.45 | 122.45 | 333.30 | 306.06 | 365.94 | 642.10 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(3.57) | (1.88) | (0.25) | (1.48) | (6.96) | (6.39) | (3.98) | (6.99) | (13.20) | — |
EV/FCF |
(3.56) | (1.88) | (0.25) | (1.31) | (6.70) | (6.15) | (3.90) | (6.85) | (13.20) | — |
Quick Ratio |
0.48 | 1.19 | 1.39 | 1.70 | 1.90 | 8.35 | 8.61 | 5.08 | 5.27 | 2.04 |
Current Ratio |
0.83 | 1.57 | 1.53 | 2.11 | 2.11 | 9.06 | 9.06 | 5.40 | 5.40 | 2.20 |
Net Debt/EBITDA |
(0.39) | (0.10) | 0.59 | 0.09 | (0.03) | 0.63 | 0.55 | 2.97 | 2.88 | 0.50 |
Debt/Assets |
74.68% | 56.43% | 23.03% | 43.35% | 55.84% | 30.41% | 37.34% | 3.16% | 5.77% | 6.92% |
Debt/Equity |
(0.77) | (1.74) | 0.90 | 5.96 | 7.68 | 1.52 | 1.87 | 6.32 | 11.55 | (0.02) |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 |
Operating CF/Net income |
0.71 | 0.54 | 0.61 | 1.30 | 1.30 | 3.55 | 3.55 | 0.98 | 0.98 | 0.82 |
Capex/Depreciation |
(0.03) | (0.01) | (0.19) | (5.08) | 0.00 | (1.39) | 0.00 | (0.40) | 0.00 | (0.35) |
Interest Coverage |
(8.61) | (8.14) | (8.89) | (14.69) | — | (57.45) | — | (21.28) | — | (185.59) |
| 197.91% | (1,738.36%) | (595.47%) | (377.90%) | 0.00% | (150.56%) | 0.00% | 57.17% | 0.00% | 51.47% | |
| (115.13%) | (98.90%) | (102.25%) | (55.63%) | 0.00% | (14.84%) | 0.00% | (46.38%) | 0.00% | (52.08%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(619.63%) | (295.24%) | (217.27%) | (115.18%) | (97.84%) | (18.13%) | (17.09%) | (34.70%) | (34.07%) | (170.38%) |
Average Days of Receivables |
0.00 | 68.30 | 79.81 | 145.85 | 2,288.77 | 24.74 | 814.31 | 37.21 | 3,843.13 | — |
Research and Development Expense of Revenue |
7,005.50% | 5,864.91% | 4,075.69% | 6,748.41% | 6,581.40% | 3,930.29% | 3,819.64% | 7,380.58% | 6,943.69% | 0.00% |
Selling, General and Administrative Expense of Revenue |
4,614.50% | 3,890.94% | 2,204.59% | 3,580.55% | 3,449.89% | 3,042.32% | 3,028.49% | 2,500.49% | 2,451.94% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
3,191.00% | 2,325.44% | 1,394.04% | 1,799.79% | 0.00% | 1,712.86% | 0.00% | 369.42% | 0.00% | 0.00% |
Graham Net Nets |
(0.46) | (0.54) | 0.00 | (0.19) | 0.02 | 0.02 | (0.04) | (0.03) | (0.40) | — |
Graham Number |
10.22 | 12.84 | 0.00 | 0.00 | 8.99 | 0.00 | 90.61 | 0.00 | 0.00 | — |
Earnings Yield |
(44.29%) | (108.29%) | (179.31%) | (47.37%) | (3.85%) | (4.15%) | (14.55%) | (10.18%) | (11.34%) | — |
Free Cash Flow Yield |
(32.12%) | (57.79%) | (100.23%) | (71.34%) | (13.21%) | (14.25%) | (14.58%) | (10.20%) | (7.25%) | — |
Revenue per Share |
0.02 | 0.05 | 0.12 | 0.15 | 0.01 | 0.23 | 0.01 | 0.24 | 0.01 | 0.00 |
Operating CF per Share |
(1.88) | (3.07) | (5.75) | (11.97) | (0.60) | (11.25) | (0.56) | (21.63) | (1.08) | (15.21) |
Capex per Share |
0.00 | 0.00 | (0.06) | (1.59) | 0.00 | (0.43) | 0.00 | (0.44) | 0.00 | (0.34) |
Free Cash Flow per Share |
(1.89) | (3.07) | (5.81) | (13.55) | (0.60) | (11.68) | (0.56) | (22.07) | (1.08) | (15.54) |
Cash per Share |
0.53 | 1.75 | 6.67 | 7.15 | 0.36 | 16.34 | 0.82 | 67.73 | 3.39 | 10.13 |
Shareholders Equity per Share |
(1.78) | (1.27) | 2.55 | 0.99 | 0.05 | 4.09 | 0.20 | 0.39 | 0.02 | (78.09) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(1.78) | (1.27) | 2.55 | 0.99 | 0.05 | 4.09 | 0.20 | 0.39 | 0.02 | (78.09) |
Free Cash Flow |
(18.58) | (21.34) | (30.50) | (44.19) | (39.01) | (35.96) | (34.62) | (19.32) | (18.93) | (13.49) |
Working Capital |
(1.80) | 5.87 | 13.52 | 15.34 | 15.34 | 48.56 | 48.56 | 51.32 | 51.32 | 5.16 |
Capital Expenditures |
(0.04) | (0.01) | (0.33) | (5.18) | (5.18) | (1.33) | (1.33) | (0.39) | (0.39) | (0.29) |
Net Current Asset Value |
(26.75) | (20.04) | (0.10) | (12.06) | (12.06) | 4.12 | 4.12 | (4.91) | (4.91) | (73.17) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.20 | 0.04 | 0.50 | 10.95 | 0.00 | 1.84 | 0.00 | 1.88 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.25 | 0.22 | 0.18 | 0.10 | 0.09 | 0.18 | 0.11 | 0.23 | 0.18 | 0.20 |
Cash ROIC |
(1,633.13%) | (113.98%) | (50.46%) | (96.40%) | (75.90%) | (43.81%) | (40.06%) | (31.27%) | (29.78%) | 23.28% |
Accounts Receivable Turnover |
0.00 | 3.30 | 3.94 | 3.97 | 0.00 | 20.66 | 0.00 | 0.19 | 0.00 | — |
Accounts Payable Turnover |
0.04 | 0.05 | 0.05 | 0.01 | 0.00 | 0.19 | 0.00 | 0.06 | 0.00 | 0.00 |
Inventory Turnover |
0.82 | 1.33 | 3.03 | 0.62 | 0.00 | 2.49 | 0.00 | 0.59 | 0.00 | 0.00 |
Average Days of Payables |
7,571.63 | 6,465.71 | 4,536.86 | 42,311.92 | 767.16 | 2,428.70 | 590.32 | 6,311.69 | 385.22 | 0.00 |
Days of Inventory on Hand |
314.07 | 354.57 | 111.61 | 603.65 | 10.94 | 51.78 | 12.59 | 1,072.54 | 65.46 | 0.00 |
Average Receivables |
— | 0.10 | 0.17 | 0.12 | 1.51 | 0.04 | 0.82 | 1.10 | 1.10 | — |
Average Payables |
1.07 | 1.37 | 2.26 | 2.47 | 2.47 | 1.52 | 1.52 | 1.01 | 1.01 | 0.89 |
Average Inventory |
0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.12 | 0.12 | 0.11 | 0.11 | 0.03 |
Average Assets |
22.73 | 39.84 | 48.42 | 53.78 | 53.78 | 65.65 | 65.65 | 41.56 | 41.56 | 31.02 |
Average Common Equity |
(13.22) | 2.27 | 8.31 | 7.92 | 7.92 | 6.47 | 6.47 | (33.72) | (33.72) | (31.39) |
Columns are period end dates